Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing TransCon-based therapies for unmet medical needs in Denmark, rest of Europe, North America, and internationally. The company offers SKYTROFA for treating pediatric patients with growth hormone deficiency; and YORVIPATH, a once-daily subcutaneous injection for the treatment of adults with chronic hypoparathyroidism. It also develops a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates. Ascendis Pharma A/S was incorporated in 2006 and is headquartered in Hellerup, Denmark.

Ascendis Pharma A/S

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Ascendis Pharma (ASND) and Corbus Pharmaceuticals (C...

Analysts Offer Insights on Healthcare Companies: Ascendis Pharma (ASND) and Corbus Pharmaceuticals (CRBP)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Amylyx Pharmaceuticals Inc (AMLX), Ascendis Pharma (...

Analysts’ Top Healthcare Picks: Amylyx Pharmaceuticals Inc (AMLX), Ascendis Pharma (ASND)

In a report released today, Leland Gershell from Oppenheimer reiterated a Buy rating on Ascendis Pharma, with a price target of $262.00. According ...

Oppenheimer Sticks to Their Buy Rating for Ascendis Pharma (ASND)

Ascendis Pharma ( ($ASND) ) just unveiled an announcement. On June 9, 2026, Ascendis Pharma’s board granted 27,030 new employee warrants, each exer...

Ascendis Pharma Grants New Employee Warrants as Part of Updated Equity Incentive Plan

In a report released on June 2, Joseph Schwartz from Leerink Partners reiterated a Buy rating on Ascendis Pharma, with a price target of $305.00. T...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	ASND	$230.83	-0.14%	908.47K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	ASND	$230.83	-0.1%	908.47K
3
4
5
6

ASND

ASND

Get Ascendis Pharma A/S Data in Excel

Get Ascendis Pharma A/S Data in Excel